Electronic ophthalmoscope for selective retinal photodisruption of the photoreceptor mosaic
09789002 · 2017-10-17
Inventors
Cpc classification
A61B3/0075
HUMAN NECESSITIES
G01B9/02091
PHYSICS
International classification
A61B3/00
HUMAN NECESSITIES
A61B3/10
HUMAN NECESSITIES
Abstract
An electronic SLO/OCT ophthalmoscope is equipped with a femtosecond (fs) laser for intra- or preretinal therapeutic use in the posterior segment of the eye. In one application the retina photoreceptor mosaic or Bruch's membrane is disrupted in such pattern that minimizes loss of visual functioning but reduces metabolic load of the outer retina. Using a beam splitter, one embodiment combines the SLO/OCT scanning beams with the therapeutic fs beam and an aiming beam. The therapeutic channel uses an independent x/y positioner and micro-deflector. Because the duty cycle is appropriate, a second embodiment can use the SLO/OCT scanners to also simultaneously scan a modulated therapeutic laser beam. A biometric OCT probe can be integrated in both configurations for focusing purpose. A method is disclosed to represent focus relevant tilting of the retina in the posterior pole. A derived apodizing “Stiles-Crawford” pupil weighting function is also independently useful for calculating light efficiency throughput of the anterior eye optics (cornea and iol/natural lens) in various circumstances.
Claims
1. An ophthalmoscope apparatus for delivering short pulsed laser applications to the retina of an eye comprising: A. an imaging channel including a first light source, a projecting means, focusing means, and at least one detection means for producing a fiduciary reference image of said retina of said eye; B. a therapeutic laser channel including a femtosecond domain pulsed laser beam second light source capable of retinal photodisruption, and a second focusing means to adjust the position in depth of the waist of said beam inside said retina of said eye, further including a deflecting means for causing a fast succession of small angle deviations of said beam; C. a coupling means including a beam splitter to combine said imaging channel and said therapeutic laser channel, and further including a positioning means for causing a slow succession of large angle deviations of said beam, to adjust the lateral position of the waist of said beam inside said retina of said eye; D. a synchronizing means for establishing an appropriate duty-cycle for said pulsed laser beam to deliver a predetermined pattern of photodisruptive applications in said retina at a desired depth.
2. The ophthalmoscope apparatus of claim 1 wherein said first and said second focusing means are same.
3. The ophthalmoscope apparatus of claim 1 wherein said detection means is from the group of confocal, coherent or mixed design.
4. The ophthalmoscope apparatus of claim 1 further including the improvement of a biometric reference channel including: A. a third light source, said coupling means aligning said third light source with said first and said second light source; B. a coherent detection means for obtaining reference optical path length distance measurements inside said eye.
5. An ophthalmoscope apparatus for delivering femtosecond domain short pulsed laser applications to the retina of an eye comprising: A. an imaging channel including a first light source, a first focusing means for said first light source, a single scanning means of predetermined sufficiently high bandwidth, and a detection means for collecting the returned light from said retina to provide a reference image of said retina of said eye; B. a femtosecond domain pulsed laser beam second light source, capable of retinal photodisruption, said single scanning means also used for positioning laterally said beam of second light source onto said retina, and a second focusing means for positioning in said retina the waist of said pulsed laser beam; C. a modulating means for adjusting the intensity of said pulsed laser beam during scanning at said sufficiently high bandwidth; D. thereby providing an appropriate duty-cycle for said pulsed laser beam to deliver a pattern of photodisruptive applications in said retina at a predetermined depth location without the need for a moving means other than said single scanning means.
6. The ophthalmoscope apparatus of claim 5 wherein said first and said second focusing means are same.
7. The ophthalmoscope apparatus of claim 5 wherein said detection means is from the group of confocal, coherent or mixed design.
8. The ophthalmoscope apparatus of claim 5 further including the improvement of a biometric reference channel including: A. a third light source, said coupling means aligning said third light source with said first and said second light source; B. a coherent detection means for obtaining reference optical path length distance measurements inside said eye.
Description
DESCRIPTION OF THE DRAWINGS
(1) Sheet 1 of 3: Anatomical and Physiological Context
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11) Sheet 2 of 3: Instrument Configurations
(12)
(13)
(14)
(15) Sheet 3 of 3: Directionality Index Determination
(16)
(17)
(18)
(19)
REFERENCE NUMERALS IN DRAWINGS
(20) 10 posterior pole of the left eye, field of view (FOV) of approximately 20 deg diagonally (12×15 deg). 12 optic disc, reference 1500 mu or 5 deg diameter 14 large retinal blood vessels, typically 100 to 150 mu diameter 16 fixation cross 18 outline of lesion, either patch of chorioretinal atrophy or area of depressed absolute retinal sensitivity 20 outline of individual laser applications or psychophysical stimuli, about 100 mu on a side 22 vertical or horizontal section of OCT (as represented in
List of Other Abbreviations and Symbols Used SLO scanning laser ophthalmoscope, ophthalmoscopy OCT optical coherence tomography MP microperimetry ARM age related maculopathy FOV field of view ^, *, / denote respectively “to the power of”, “multiplied by”, “divided by” θ, μ, λ, ρ, Δ, π respectively denote theta, mu, lambda, rho, Delta, pi z(½) depth location, defined at particular location between parentheses, typically at half depth w(f) waist radius at particular location indicated between parentheses, e.g. at focus or original a( ) absorption or attenuation coefficient for particular wavelength and absorber d diameter deg degree(s)
DETAILED DESCRIPTION AND OPERATION OF THE INSTRUMENT
(21) Representative embodiments of the electronic ophthalmoscope have been described in U.S. Pat. Nos. 7,374,287 and 7,703,922. The art of combining such instrument with various therapeutic light sources of different pulse duration has been described in U.S. Pat. Nos. 5,892,569, 5,923,399, 5,943,117, 6,186,628 and 6,789,900.
(22) The principles and applications of scanning laser ophthalmoscopy, optical coherence tomography and microperimetry are also described in detail in the publications referenced before. Below we describe the operational environment of an ophthalmoscope that is capable of selectively disrupting in a controlled manner a pre-defined part of the photoreceptor mosaic of the retina or Bruch's membrane.
(23) I. Anatomical and Physiological Considerations
(24) The photoreceptor-RPE complex is by far the most active metabolic tissue in the human body, and even more so in the macular area. A huge volume of oxygen is needed to drive the Wald's visual cycle and to maintain the so-called dark current loop. In order to maintain an adequate oxygen gradient across this complex as indicated in
(25) We have proposed before to selectively deactivate in a well-defined pattern the metabolically very active photoreceptor population in the macular area. In particular the mitochondria rich ellipsoid part of the PR IS layer 70, at the IS/OS junction reference layer 74 is targeted, but optionally also the RPE layer 82. This “pruning” should be done in such manner that from a psychophysical point of view only acceptable changes to the subject's visual perception occur, while creating so-called “oxygen windows” or “fountains” that let unconsumed oxygen diffuse efficiently into the adjacent retina. A first precautionary principle here is sparing of the inner retinal layers 42, the ONL 64 and HFL 62, and avoiding damage to the choroid. A second principle is to confine the treatment in a targeted area to the smallest group of photoreceptors possible.
(26) II. Available Therapeutic Laser Sources and their Mode of Action
(27) At least for the wet form of ARM several distinct therapeutic approaches that all involve laser light of circa 800 nm wavelength but of dramatically different exposure durations have been developed. They are in part the object of invention in the referenced patents and referenced publications. Relatively long and extended exposure to light (in the order of 10^2 of seconds) is used in photodynamic therapy (PDT), a technique based on a photochemical mode of action. The historically earliest form of laser treatment uses a thermal mode of action and relatively confined applications about 10^(−1) seconds. In order to selectively coagulate or vaporize the RPE cells and prevent the thermal damage from spreading beyond those cells, even shorter pulses in the microsecond range are applied. Thermal applications require a relatively strong absorber of light, in this case the abundant melanin granules of the RPE, to be present exclusively in the targeted volume. Thus, such methods cannot be used for selectively disabling the photoreceptors or drilling holes in Bruch's membrane. A suggestion was made in the related U.S. Pat. No. 6,789,900 to use a CW 1064 nm laser to exactly do this. However, a still relatively low absorption of light of this wavelength by water (melanin absorbs this wavelength far more efficiently) and the ubiquity of this absorber in and around the photoreceptors makes this approach rather problematic.
(28) Shorter exposure duration lasers in the nanosecond, picosecond and femtosecond range, relying on a photodisruptive instead of thermal absorptive mode of action, have been introduced for surgical applications involving the cornea and lens of the eye. The recently introduced femtosecond laser has certain advantages over the nanosecond and picosecond range lasers that make them far more suitable for precision applications at the retinal level, our intended usage. A detailed theoretical explanation for these advantages is to be found in Ching-Hua Fan, applied optics vol. 40, nr. 18, pp. 3124-3131, 2001. In brief, they include the negligible heat diffusion, minimal plasma absorption and shielding effects, smaller laser fluences resulting in a high spatial resolution of the shape of the lesion, a deterministic optical breakdown rather than statistical permitting control of the ultra fast breakdown by changing the irradiated laser intensity. Also, the length of the pulse is shorter than or about the length of the focal volume, i.e. in the neighborhood of 30 mu for a 100 fs pulse. Within an approximate cylindrical volume of focus, the breakdown will start somewhere up the beam path and progress predictably toward the focus.
(29) A good example of an appropriate femtosecond laser source is the “Origami—10” from OneFive GmbH, Switzerland. It has a tunable center wavelength between 1025 and 1070 nm, a pulse duration of 100 fs or less, a pulse repetition rate of 40 MHz (25 ns intervals) to 1.3 GHz (1 ns intervals), a peak pulse energy of 5 nJ (peak power of 22 kW), optionally higher. The output beam quality is diffraction limited. The pulses can be synchronized to an external clock. The bandwidth is transform limited according to tau(p)*Delta(freq)=0.32 resulting in a 30 nm Gaussian bandwidth. Similar sources of interest have a center wavelength between 514 and 532 nm and between 765 and 785 nm.
(30) III. General Description and Control of the Optical Environment
(31) We now consider in some more detail the impact of differences in absorption in vivo at 532, 800 and 1050 nm for water, melanin (melanosomes) and (oxy)hemoglobins. The law of Lambert-Beer, I(x)/I(o)=e^[−a*x], can be applied. Also, Jacques has estimated the absorption coefficients a for RPE melanin in vivo for a range of wavelengths to be a=[6.49*10^12*lambda(nm)^(−3.48)] [cm.sup.−1] (Photochem. Photobiol. vol. 53, pp. 769-775, 1991). This results in values of 600/cm at 800 nm and 200/cm at 1050 nm. For reference at 532 nm the value is 1800/cm. From this we can conclude that as the wavelength increases, melanin gradually absorbs less, though still significant at 1050 nm. If we consider a layer of melanin pigment of 5 to 10 mu at the level of the RPE 82, then 10 to 20% of the intensity will be absorbed. In contrast, water absorbs insignificantly at 532 nm, minimally at 800 nm with an absorption coefficient of 2*10^(−2)/cm, then steadily increases towards 1050 nm with an absorption coefficient of about 5*10^1/cm, being a 40 fold increase. Yet, this is still insignificant at the PR/RPE level, but it of course explains why the initial intensity of a 1050 nm beam at the cornea is reduced to about 28% of its initial value at the PR layer (including both absorption and scatter effects). For oxyhemoglobin, predominantly present in the RBCs of the CC layer 90, absorption is very significant, but still less than for melanin, at 532 nm. It has some absorption in the 800 to 1050 nm wavelength interval, stronger than water. Some possibilities are predicted from the above data. The RPE 82 will be a relatively low resistance barrier to the photodisruptive effect of a focused fs laser beam, especially at 1050 nm. With sufficient intensity, single or repeat photodisruptive impacts can cross the RPE barrier 82 and further drill a hole into Bruch's membrane 86 and the inner very thin lining of the choriocapillary layer 90 endothelium cells. In itself, this could be of therapeutic benefit provided at least that the endothelium cells are capable of self-sealing. If the perforations are smaller than 8 mu, no RBCs can pass. With this in mind, a particular treatment protocol might use a more elaborate double laser beam exposure technique, the first application directed at removing the melanin barrier by destroying selectively RPE cells 82 in a manner described in previous patents. Another possibility is bringing a dye similar to fluorescein or indocyanin green into the retinal circulation at the time of treatment. This dye should absorb significantly around the center wavelength of the fs laser and will then act to protect the choriocapillary layer 90.
(32) With aging, the natural lens of the human eye 98 can gradually develop a cataract, limiting considerably the possibility of diffraction limited imaging and therapy at the retinal level. Even before a manifest cataract develops, changes in the lens will include an increase in higher order aberrations and scattering of light. Such scattering will reduce transparency and again increase the size of the theoretical diffraction limited spot size. In order to avoid these problems and also to correct the eye's refraction as much as possible before fs laser treatment, an elective cataract surgery procedure can be performed using the “Bag-in-the-lens” intra-ocular lens of Tassignon, U.S. Pat. No. 6,027,531. In summary, this routine implantation technique allows a reliable active optical centration of the 5 mm optical diameter lens and prevents any secondary capsular opacification to occur. After stabilization, any remaining spherical or astigmatic error is corrected (this correction can be provided by the electronic ophthalmoscope or contact lens). It is useful to obtain with an aberrometer the Zernike polynomial coefficients of residual wavefront aberrations for an apodized 5 mm pupil and centered on the line of sight. It is also useful to obtain biometric data that are based on a reflective low optical coherence technique, such as optical path lengths. These data are now routinely collected pre and post cataract surgery.
(33) We now introduce a practical index that will be of use in focusing the therapeutic laser beam over an extended area of the reference image 120 (much larger than an isolated application area 20) (
(34) IV. The SLO, OCT and Therapeutic Beams and Channels
(35) Beam Optics
(36) We will first discuss generalities concerning the focusing of the different laser or superluminescent diode beams in our application, then proceed to a description of two preferred channel configurations.
(37) As a reminder, for Gaussian beams 38 (
(38) In contrast, for a broad-band light beam, laser or SLD, that is used in a coherence gated configuration 50 as in the OCT, the much smaller z-resolution is under certain conditions estimated as follows: 0.44 lambda(mean)^2/Delta(lambda); for a center wavelength of 1050 nm and bandwidth of 80 nm this would correspond to a z-resolution of 6 mu, at 860 nm this improves to 4 mu.
(39) In practice our SLO, OCT and therapeutic beams are only approximately Gaussian. We have to take into account truncation effects and the beam quality or propagation factor M. In brief, the divergence angle theta=M^2 lambda/(pi*w(r)). This M^2 is better than 1.1 for the femtosecond lasers that we described.
(40) We like to refer to a rule of thumb for estimating the practical focused FWHM diameter of beams. Both from an imaging and therapeutic perspective the FWHM diameter, instead of the 1/e^2 defined one, seems reasonable to use. Truncation, in the interest of saving power, will be limited to the unit ratio.
(41) This rule of thumb is that the diameter at the focused waist is d=K*λ*f/#; where f(i) is the image focal length of 22.28 mm and K(FWHM)=1.13 if the truncation index is unity, i.e. the limiting aperture in the optical system is equal to the Gaussian diameter of the beam. More details can be found in the documentation from optical components manufacturer Melles-Griot.
(42) From the foregoing it is evident that a near-Gaussian laser beam used at f/10 (with a FOV in the SLO of 20 deg diagonally, 1 pixel representing 1.6 minarc or 8 mu), at 500, 800 or 1000 nm will have a practical FWHM diameter at the focusing waist of 5, 8 and 10 mu respectively. It is important to note that this is sufficient for our diagnostic and therapeutic applications. In the case f/5 is used, those diameters are respectively halved, at least in theory, and some adaptive optics (spherical aberration) may be required.
(43) In our embodiments a combination of 500, 800 mu and 1000 mu light sources are sometimes used. Therefore, differences in refraction index in a watery solution should be considered. Under fixed conditions of salinity, temperature etc, this refraction index is 1.3360, 1.3275 and 1.3250 respectively. A 0.75 D and 0.25 D difference in focusing between 550 nm, 800 nm and 1 mu can be adjusted for optically.
(44) Channel Configurations
(45) When considering options for coupling therapeutic laser sources to the scanning laser ophthalmoscope or another reference image device, an appropriate duty cycle for the therapeutic laser beam is of paramount importance, as is focusing. This has been explained in the referenced U.S. Pat. No. 5,892,569. For example, in a thermal photocoagulation procedure it is impossible to use the same scanning laser source for both imaging and therapeutic purposes as the scanning beam is only for less than 90 ns on a specific location, only to return 30 ms later to the same spot. Tissue temperature cannot be raised significantly in this way. The solution proposed in U.S. Pat. No. 5,892,569 is to couple and synchronize an external therapeutic beam with an x/y positioner to deliver pulses in the ms range.
(46) Even when dealing with shorter duration pulses of 5 microseconds delivered at 2 ms intervals, in the microsecond regime for selective microphotocoagulation of the RPE, the SLO raster scanning is too fast. The solution here is to couple again an external therapeutic source to the SLO and to pass the beam through a second scanning system, e.g. an acousto-optic x/y microdeflector, to provide the correct duty cycle. In this manner the temperature can be raised in successive steps locally, even to the level of vaporization, without spreading significant heat to the neighboring tissue. The method has been reported in the referenced U.S. Pat. No. 6,789,900.
(47) When using the femtosecond laser source to obtain photodisruptive effects in a watery solution, even shorter pulses in the order of 100 fs are applied at 25 ns to 1 ns intervals. This opens the possibility to use effectively the same scanning system or even scanning lasers for imaging and therapy, which is innovative. The method of using a second scanning system is also still possible. Each approach has some distinct advantages.
(48) In
(49) In theory, when using a 10 deg FOV reference image, the laser beams operating at around f/5 will have a Rayleigh range of 30 mu and match therefore the length of the fs pulse. In the 20 deg FOV this would be around 125 mu as previously mentioned. Even if different layers are intentionally or not exposed between the RPE layer and outer part of the ONL, the expected therapeutic outcome might be similar. Thus, some uncertainty in focusing is tolerable.
(50) In
(51) In
(52) An aiming beam configuration as in
(53) V. Feedback
(54) The therapeutic efficacy of the fs laser treatment modalities as described can be assessed both by subjective and objective means. The subjective method employs the non-invasive technique of microperimetry MP. This method has been extensively elaborated upon by the author in the references. In brief, absolute dark adapted thresholds and speed of recovery from bleaching are related to the amount of photopigment that is capable of catching light quanta and the rate of renewal of such photopigment. For example, cone functioning at 532 or 650 nm can be evaluated if the directionality of testing (entrance location) and pre-adaptation bleach are properly controlled. The application size equivalent to Goldmann III or a larger area can be used. Because of the specific neuronal processing of the signals coming from activated cones, an improvement could be detected after treatment. Other assessment strategies involving both cones and rods can be envisioned.
(55) A very important role of MP is to verify that treatment will not adversely affect minimal retinal resolution and sensitivity levels in the treated areas. Another role as mentioned before is the possibility to predict the very early phases of ARM when such treatment can still postpone the onset of the disease by a decade or more.
(56) The objective method of treatment assessment involves the measurement of actual PO2 values within the retina (Shonat et al., Applied Optics, vol. 31, nr. 19, pp. 3711-3718, 1992). This is an in-vivo invasive technique based on the principle phosphorescence lifetime imaging. The oblique incidence of a narrow 532 nm laser beam through the relevant layers can be used for this purpose. A porphyrin based dye is allowed to diffuse into the retina (intravitreal injection required). A Stern-Volmer relationship is used to convert lifetime phosphorescence to oxygen tension.
SUMMARY
(57) Embodiments of an electronic ophthalmoscope capable of selectively photodisrupting the photoreceptor layer or perforating Bruch's membrane in a specific pattern have been disclosed. The operational environment necessary to realize this goal includes the following: (1) Physiological considerations and rationale for treatment; (2) Anatomical considerations including dimensional aspects; (3) Desired short pulse laser sources and their physical properties of interest; (4) Significant parameters of and control of the optical environment (intra-ocular scattering, absorption, tilting of retina); (5) Beam optics, focusing issues; (6) Preferred channel combinations; (7) Ways to get feedback on the efficiency of the treatment.
(58) Although the descriptions of preferred embodiments contain many specifications, these should not be construed as limiting the scope of the invention but as merely providing an illustration of the presently preferred embodiments. Other embodiments including additions, subtractions, deletions, or modifications will be obvious to those skilled in the art and are within the scope of the following claims. The scope of the disclosure should be determined by the appended claims and their legal equivalents, rather than by the examples given. As a particular example of this, the reference SLO channel can be designed with traditional laser sources, but now also with superluminescent diode laser sources; the scanning systems can include polygons, or galvos, one or two dimensional confocal systems based on spot or line scanning configurations can be used. The fiduciary channel can be a traditional optical fundus camera configuration. Still other embodiments may take full advantage of adaptive optics by incorporating e.g. deformable mirrors and a wavefront measuring device, in intra- and preretinal surgery.